Bionaturis is a clinical-stage company that codevelops a new generation of biopharmaceutical products to hit unmet medical needs. Bionaturis´ pipeline is focused on rare and neglected diseases and cutting-edge solutions for veterinarian applications.
BNT001:
Biobetter of recombinant human glucocerebrosidase for Gaucher disease. Lead optimization. Non-clinical studies Q3 2012
BNT003:
Recombinant multivalent oral vaccine for Shigellosis in humans. Lead optimization
BNT004:
Intranasal recombinant vaccine for nematodes in livestock. Efficacy, effectiveness, and toxicity tested in both rodents and lambs trials. Ready to out-licensing
BNT005:
Canine visceral leishmaniasis recombinant prophylactic and therapeutic vaccine. Efficacy and toxicity tested in rodent challenges.